- Research article
- Open Access
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
© The Author(s). 2018
- Received: 29 March 2018
- Accepted: 27 June 2018
- Published: 16 July 2018
Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors.
This was a retrospective analysis of 97 consecutive patients with stage IV melanoma who were treated with nivolumab. Baseline NLR and derived (d) NLR were calculated and, along with other characteristics, correlated with progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analyses. The best cutoff values for NLR and dNLR were derived using Cutoff Finder software based on an R routine which optimized the significance of the split between Kaplan-Meier survival curves.
In univariate analysis, increasing absolute neutrophil count (ANC), NLR, dNLR and lactate dehydrogenase (LDH) (continuous variables) were all significantly associated with OS. Only NLR (hazard ratio [HR] = 2.85; 95% CI 1.60–5.08; p < 0.0001) and LDH (HR = 2.51; 95% CI 1.36–4.64; p < 0.0001) maintained a significant association with OS in multivariate analysis. Patients with baseline NLR ≥5 had significantly worse OS and PFS than patients with NLR < 5, as did patients with baseline dNLR ≥3 versus < 3. Optimal cut-off values were ≥ 4.7 for NLR and ≥ 3.8 for dNLR. Using this ≥4.7 cut-off for NLR, the values for OS and PFS were overlapping to the canonical cut-off for values, and dNLR< 3.8 was also associated with better OS and PFS.
Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values. NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma.
- PD-1 inhibitor
- Neutrophil-to-lymphocyte ratio
Improved understanding of cancer and the role of the immune response has resulted in the development of new therapies, including immune checkpoint inhibitors targeting the cytotoxic T-lymphocyte-associated protein (CTLA)-4 (e.g. ipilimumab) and programmed death (PD)-1 receptors (e.g. nivolumab and pembrolizumab). These agents have revolutionized the treatment and outcomes of various cancers, in particular melanoma, with improved long-term disease control and prolonged patient survival [1, 2].
Nivolumab (Opdivo®, Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody that blocks the PD-1 receptor, a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with its ligands PD-L1 or PD-L2 expressed on antigen-presenting cells and on tumor cells results in inhibition of T-cell proliferation and cytokine secretion, potentiating T-cell responses. Nivolumab has demonstrated clinical activity in previously treated and treatment-naïve patients with advanced melanoma, with overall response rates (ORR) ranging between 20 and 40% in patients treated at various dose levels [3–5]. Nevertheless, a significant portion of patients do not benefit from nivolumab treatment. Given that immunotherapy can be associated with significant toxicity as well as high treatment costs, it is important that those patients most likely to respond to treatment are better identified. To achieve this involves the recognition and validation of novel biomarkers predictive of treatment outcomes. Any such biomarkers should ideally be simple and easy-to-use, inexpensive and readily available.
In recent years, it has become evident that cancer-related inflammation responses, such as increased and defective myelopoiesis, and both local and systemic inflammation, have an important role in tumorigenesis, disease progression and patient prognosis [6, 7]. Therefore, predictive biomarkers that reflect the inflammatory response to treatment may help clinical decision making in the management of patients with melanoma. Systemic inflammation is associated with alterations in peripheral blood leukocytes that can be captured by the neutrophil-to-lymphocyte ratio (NLR) . Several studies have demonstrated that NLR predicts outcomes in patients with a variety of solid cancers [9, 10]. In melanoma, raised leukocyte, neutrophil and monocyte counts, as well as high NLR have been associated with poor prognosis in patients with advanced melanoma, most of whom were receiving immunotherapies [11, 12]. Furthermore, in a recent Italian study, elevated NLR and derived (d) NLR were independently and significantly associated with an increased risk of death and disease progression in melanoma patients receiving ipilimumab .
This retrospective study investigates the role of the NLR and dNLR as predictive markers of response to treatment with nivolumab in patients with advanced melanoma.
A total of 97 consecutive patients with stage IV melanoma who were treated with nivolumab 3 mg/kg in a 60-min intravenous (IV) infusion every 2 weeks at the NCI Fondazione “G. Pascale” of Napoli between February 2015 and February 2017 had available hematological values and were included in this analysis. For all patients, clinical data (white blood cell [WBC] count, absolute lymphocyte count [ALC], absolute neutrophil count [ANC], serum lactate dehydrogenase [LDH], and other clinical data, including BRAF status, brain metastasis, lines of prior treatment, and response) were collected before starting nivolumab treatment and until last follow-up. Patients were treated with nivolumab until disease progression, intolerable toxicity and/or the investigator’s decision. Tumor assessment was performed at baseline, at week 12, and every 12 weeks thereafter, and clinical response were classified according to response evaluation criteria in solid tumors (RECIST) .
Descriptive statistics were used to summarize patient and treatment characteristics. NLR was calculated as NLR = ANC/ALC and dNLR was calculated as dNLR = ANC/(WBC − ALC). Progression-free survival (PFS) was determined from the first cycle of treatment to disease progression documented by imaging, or death (event), or last follow-up (censored). Overall survival (OS) was calculated from the first cycle of treatment to death (event) or last follow-up (censored). Multivariate Cox proportional hazard models were used to investigate associations of NLR with survival, adjusted for baseline characteristics. Results were presented as hazard ratios (HR) with 95% confidence intervals (CIs). The best cutoff was derived using Cutoff Finder software  based on an R routine which optimized the significance of the split between Kaplan-Meier survival curves measured by the log-rank test. Statistical analyses were performed with IBM-SPSS version 21.0.
Baseline patient characteristics
N = 97
Gender, N (%), Female/Male
42 (43.2) / 55 (56.7)
Age, years, median (range)
Number of previous therapies, N (%)
Central nervous system (CNS) metastasis
Baseline lactate dehydrogenase, N (%)
≤ upper limit of normal (ULN)
B-RAF, N (%):
As of May 2017, 44 patients (45.4%) were still alive. The median PFS was 4 months (range 0–26) and median OS was 6 months (range 2–26); about 10% of patients had started therapy no more than 6 months earlier. There was no significant difference in OS by BRAF status (P = 0.65). Overall, 57 patients (58.8%) had progressive disease (PD), 20 patients (20.6%) had a partial response (PR) and 20 patients (20.6%) had stable disease (SD). The disease control rate (DCR) was 41.2%.
At baseline, median WBC was 8620/μL cells in patients who had PD, 7540/μL in patients with SD and 6645/μL in patients with PR (median 7.000/μL in patients with disease control). A total of 22 patients (22.7%) had neutrophilia (ANC > 7.5) before the start of treatment.
In univariate analysis, elevated ANC (> 8000) was associated with poor prognosis, with a median of OS of 2.6 months compared to 16.0 months in patients with normal ANC (P < 0.0001).
Using median ANC as cut-off value, median OS was 16 months (95% CI: 7.6–24.4) in patients with ANC < 5.4 compared to 5.7 months (95% CI: 2.6–8.8) in patients with ANC ≥5.4 (HR 2.04; 95% CI: 1.17–3.57; P = 0.01). Median PFS was also increased in patients with ANC < 5.4 compared with ANC ≥5.4 (8 months [95% CI: 1.6–14.4] versus 3 months [95% CI:1.5–4.5]) but this was not statistically significant (HR 1.60; 95% CI: 0.98–2.61; P = 0.06) (See Additional files 1 and 2).
NLR and dNLR
At baseline, 27 (27.8%) patients had a NLR ≥5 and 31 (32%) patients had a dNLR ≥3, the cut-offs most often indicated in the literature. Using Harrell’s c-index to determine the prognostic power of NLR and dNLR, we obtained a good prognostic value for both, with c = 0.72 (95% CI: 0.67–0.77) for NLR and c = 0.70 (95% CI: 0.65–0.75) for dNLR.
The proportion of patients with an NLR ≥5 was 20% (4/20) in patients with a PR, 5% (1/20) in patients with with SD and 38.6% (22/57) in patients with PD.
In order to better investigate the role of NLR and dNLR, the optimal cutoffs were derived by maximizing the significance assessed by the log-rank test; these values were 4.7 for NLR and 3.8 for dNLR. The performance of an NLR cut-off value of 4.7 was overlapping with 5 as cut-off value, Median PFS and OS were also significantly longer in patients with dNLR < 3.8 compared to ≥3.8 (see Additional files 1 and 2).
In the subgroup of 27 patients with brain metastases, NLR < 4.7 and dNLR < 3.8 were both significantly associated with improved OS and PFS in univariate analysis. However, in multivariate analysis, only NLR < 4.7 was associated with significantly longer OS (HR 3.22, 95% CI: 0.99–10.51) and PFS (HR 2.55, 95% CI: 0.98–6.65) (See Additional files 1 and 2).
Cox regression models on overall survival and progression-free survival
Univariate HR, 95% CI, P-value
Multivariate HR, 95% CI, P-value
Univariate HR, 95% CI, P-value
Multivariate HR, 95% CI, P-value
Sex (M vs F)
1.71 (0.96–3.05), P = 0.07
1.35 (0.82–2.21) P = 0.24
1.00 (0.98–1.02), P = 0.72
1.00 (0.98–1.01) P = 0.74
Lines of treatment:
P = 0.55
P = 0.63
2 vs 1
≥ 3 vs 1
BRAF (mutant vs wild-type)
1.14 (0.64–2.04), P = 0.65
1.32 (0.80–2.19) P = 0.28
Brain metastases (yes vs no)
1.03 (0.56–1.87), P = 0.93
1.30 (0.77–2.18) P = 0.32
Lactate dehydrogenase (≥454 vs < 454)
3.06 (1.69–5.57), P < 0.0001
2.51 (1.36–4.64), P = 0.003
2.16 (1.18–3.99) P = 0.01
1.74 (1.03–2.94) P = 0.04
Absolute neutrophil count (≥5.4 vs < 5.4)
2.04 (1.17–3.57), P = 0.01
1.60 (0.98–2.61) P = 0.06
White blood cell count (≥7.6 vs < 7.6)
1.57 (0.91–2.73), P = 0.11
1.55 (0.95–2.54) P = 0.08
Neutrophil-to-lymphocyte ratio (≥5.0 vs < 5.0)
3.53 (2.02–6.16), P < 0.0001
2.85 (1.60–5.08), P < 0.0001
2.53 (1.53–4.18) P < 0.0001
2.10 (1.23–3.59) P = 0.007
Derived neutrophil-to-lymphocyte ratio (≥3.0 vs < 3.0)
2.70 (1.55–4.69), P < 0.0001
2.50 (1.48–4.23) P = 0.001
Melanoma is an aggressive cancer with frequent relapse and a high potential for metastasis. Nevertheless, in recent years, the range of therapeutic options for melanoma has been greatly improved with the introduction of immunomodulatory antibodies as well as molecular targeted drugs . These agents have shown promising results, but not all patients benefit and toxicity can be a significant concern. Because of this, it is important to be able to identify which patients are most likely to benefit from treatment.
In recent years, NLR has been extensively studied as a prognostic marker in patients with solid tumors on the basis that it reflects the inflammatory response to cancer. In patients with advanced cancer, there is usually a change in peripheral blood cell composition that is suggestive of an expansion in the myeloid component (neutrophils and monocytes) and a reduction in the lymphoid compartment.
A number of studies have shown that systemic inflammation markers are associated with the outcome of malignant melanoma patients, including those treated with ipilimumab [13, 17, 18]. In 69 patients with metastatic melanoma, pre-treatment NLR was identified as an independent marker for response in multivariate analyses, with patients with baseline NLR ≥5 having significantly worse PFS and OS compared with those with a NLR < 5 . Similarly, a significant association between elevated NLR and worse survival was significant after adjustment for potential confounders in an analysis of 58 patients treated with ipilimumab . In another study of patients with unresectable stage III-IV melanoma, elevated NLR (≥5) was associated with worse OS, PFS, and clinical response . In addition, increasing NLR from baseline during treatment was correlated with worse OS and PFS in patients treated with ipilimumab but not those treated with vemurafenib, suggestive of a predictive value for response to immunotherapy but not targeted drugs. In another recent study, in 162 melanoma patients, 22.5% receiving ipilimumab, elevated baseline dNLR (≥3) was independently and significantly associated with an increased risk of death and disease progression .
Elevated baseline NLR ≥ 5 has also been associated with worse outcomes in patients treated with nivolumab, although this was in non-small-cell lung cancer (NSCLC) rather than melanoma . In a retrospective analysis of 175 patients with previously treated advanced NSCLC, NLR ≥5 was independently associated with reduced OS (median 5.5 vs. 8.4 months; HR 2.07, 95% CI: 1.3–3.3; p = 0.002) and PFS (median 1.9 vs. 2.8 months; HR 1.43, 95% CI: 1.02–2.0; p = 0.04). Data from the Italian nivolumab extended access program (EAP) has also reported that NLR (≥3) was a prognostic factor for OS in patients with metastatic renal cell cancer treated with nivolumab .
In this study, which is the first to report an association between NLR and outcomes in patients with advanced melanoma treated with nivolumab, we analyzed the predictive power of baseline NLR and dNLR in a small retrospective cohort of patients. Despite the small number of patients, both NLR and dNLR were good predictors of survival when baseline levels were lower than cut-off values. The optimal cut-off values were shown to be ≥4.7 for NLR and ≥ 3.8 for dNLR, with the NLR cut-off value a more robust predictor than the dNLR value. NLR was predictive of survival independent of BRAF status (data not shown). Lower baseline LDH also correlated with a better response and survival, consistent with several previous studies [23–25], which was maintained in multivariate analysis. Patients with two or three risk factors of elevated NLR, ANC and LDH had worse survival than patients with none or just one of these factors alone. These results suggest that the systemic inflammatory response is a potent stimulator of cancer progression in established disease. Elevated NLR suggests a systemic inflammatory state and can be indicative of neutrophilia, lymphopenia, or a combination of both.
The biggest limitation of this study is the low number of patients that we have analyzed and validation is required in larger prospective studies. The benefits that can be gained with the validation of these parameters may be significant because they offer the potential for a low-cost, non-invasive and easy-to-read test that can be used to help define the patient’s status, prognosis, and response to therapeutic treatment.
Neutrophilia can occur in cancer patients at a peripheral level, but neutrophils can also localize to the tumor due to multiple factors, including general inflammatory signals such as IL-1 and TNF-α . Although many mechanisms are unclear, neutrophils are thought to primarily propagate a pro-tumor environment promoting angiogenesis and tumor growth, degrading the extracellular matrix and providing favorable conditions for metastasis, and potentiating genome instability and tumor evolution . A recent study also demonstrated that the expression of PD-L1 on tumor infiltrating neutrophils could functionally inhibit the activation of T cells . Lymphopenia in the context of cancer also suggests more aggressive disease progression. For these reasons, whether due to neutrophilia or lymphopenia, elevated NLR physiologically suggests an inability of the immune system to suppress cancer progression, and thus it can be an index for OS and PFS. Because the NLR and dNLR are obtained from complete blood counts, their use does not involve additional procedures for patients or extra resources and associated costs for healthcare providers. If it can be shown that NLR and dNLR are predictors of response to immunotherapy as well as being prognostic markers, their use in clinical practice could allow better patient selection and optimal clinical management.
A special thanks to Alessandra Trocino, for providing excellent bibliography service and assistance.
MC and PAA contributed to the Study concepts and study design. Data acquisition was performed by MC, DM, GM and EC. All the authors contributed to the quality control data, analysis and interpretation of data. The statistical analysis was performed by DG. The manuscript preparation was performed by MC and DG and edited by PAA. All authors reviewed the manuscript and accepted it.
Ethics approval and consent to participate
Consent for publication
We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.
We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.
P.A. Ascierto has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune. He also received Research funds from Bristol Myers-Squibb, Roche-Genentech, Array.
Antonio M. Grimaldi received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis and Roche Genentech, and had consultant/advisory role for Merck Sharp & Dohme and Novartis.
E. Simeone participated to advisory board for Bristol-Myers Squibb and received honoraria from Bristol-Myers Squibb, Novartis and Merck Sharp & Dohme.
G. Palmieri has advisory role for Incyte, MSD, Novartis, Pierre-Fabre.
All the other authors have no conflict of interest to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.View ArticlePubMedGoogle Scholar
- Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.View ArticlePubMedGoogle Scholar
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer- related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503.View ArticlePubMedGoogle Scholar
- Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5–14.PubMedGoogle Scholar
- Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumagai S, Marumo S, Shoji T, Sakuramoto M, Hirai T, Nishimura T, et al. Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma. Lung Cancer. 2014;85:457–64.View ArticlePubMedGoogle Scholar
- Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2017;27:732–8.View ArticleGoogle Scholar
- Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol. 2015;38:252–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.View ArticlePubMedGoogle Scholar
- Budczies J1, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.View ArticlePubMedPubMed CentralGoogle Scholar
- Tang T, Eldabaje R, Yang L. Current status of biological therapies for the treatment of metastatic melanoma. Anticancer Res. 2016;36:3229–41.View ArticlePubMedGoogle Scholar
- Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62:1021–8.View ArticlePubMedGoogle Scholar
- Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112:1904–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2016;174:146–51.View ArticlePubMedGoogle Scholar
- Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et al. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBio Medicine. 2017;18:56–61.Google Scholar
- Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7.View ArticlePubMedGoogle Scholar
- De Giorgi U, Procopio G, Guida A, Bearz A, Buti S, Basso U, et al. Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP). Ann Oncol. 2017;28(suppl_5):v295–329.View ArticleGoogle Scholar
- Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22:5487–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, et al. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunol Immunother. 2016;65:1395–400.View ArticlePubMedGoogle Scholar
- Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int Immunopharmacol. 2016;40:466–73.View ArticlePubMedGoogle Scholar
- Hashimoto T, Ohno Y, Nakashima J, Gondo T, Ohori M, Tachibana M. Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma. World J Urol. 2013;31:953–8.View ArticlePubMedGoogle Scholar
- Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, et al. VEGF release by MMP-9 mediated heparansulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 2008;44:1904–13.View ArticlePubMedGoogle Scholar
- He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:141.View ArticlePubMedPubMed CentralGoogle Scholar